Showing results (281-290 of 336) with videos related to
Sort By:
Pageof 34
Nature|March 17, 2016
Deletions linked to TP53 loss drive cancer through p53-independent mechanismsYu Liu, Chong Chen, Zhengmin Xu, et al.International Journal of Hematology|January 3, 2021
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in ChinaJuan Du, Baijun Fang, Jian Li, et al.Clinical Lymphoma, Myeloma & Leukemia|June 10, 2021
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) StudyJin Lu, Weijun Fu, Wei Li, et al.Nature Communications|July 9, 2026
Intracellular iron homeostasis-regulated epigenetic reprogramming contributes to -7/del(7q) leukemiaJianan Zheng, Yiman Peng, Xintong Deng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 13, 2025
High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in ChinaYuewen Wang, Yi Xia, Zhenyang Gu, et al.Blood Advances|December 3, 2024
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemiaYing Wang, Lulu Lv, Yongping Song, et al.Vaccine|April 19, 2011
Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherinZhiwei Zhao, Yaqin Yao, Zhenyu Ding, et al.Cell Death & Disease|February 11, 2022
ALCAM regulates multiple myeloma chemoresistant side populationFangfang Wang, Zhang Dan, Hongmei Luo, et al.Ejhaem|July 31, 2026
Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China CohortZhen Cai, Zhongjun Xia, Aili He, et al.Pageof 34